When should a patient consider changing therapy?

When should a patient consider changing therapy?

So people that are on the BTK inhibitors like ibrutinib or acalabrutinib. We'll start to see some subtle signs, potentially of disease progression, which may be the first hint that we may need to start talking about treatment. This could be your lymph nodes had shrunk for a good period of time, but now they're starting to come back or we're starting to see some new blood count changes or a high white blood cell count again. Those might be signs that the treatment may not be working anymore, which is where we start to talk about switching treatments, but probably the most common reason that we have to switch treatments is because of, intolerance, meaning that side effects may become more significant than what the treatment's worth. So if people who are on ibrutinib, for instance, develop atrial fibrillation and need to get started on a blood thinner, we may decide that the BTK inhibitors are not the best choice for them, and we'll have to switch treatments for something like that. So it's either one disease progression, meaning that the CLL, has found a way to outsmart the treatment or two, side effects are playing a significant role in impacting patient's quality of life.